{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:15:43Z","timestamp":1790572543632,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T00:00:00Z","timestamp":1538870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a deadly cancer that is caused by asbestos exposure and that has limited treatment options. The current standard of MPM diagnosis requires the testing of multiple immunohistochemical (IHC) markers on formalin-fixed paraffin-embedded tissue to differentiate MPM from other lung malignancies. To date, no single biomarker exists for definitive diagnosis of MPM due to the lack of specificity and sensitivity; therefore, there is ongoing research and development in order to identify alternative biomarkers for this purpose. In this study, we utilized primary MPM cell lines and tested the expression of clinically used biomarker panels, including CK8\/18, Calretinin, CK 5\/6, CD141, HBME-1, WT-1, D2-40, EMA, CEA, TAG72, BG8, CD15, TTF-1, BAP1, and Ber-Ep4. The genomic alteration of CDNK2A and BAP1 is common in MPM and has potential diagnostic value. Changes in CDKN2A and BAP1 genomic expression were confirmed in MPM samples in the current study using Fluorescence In situ Hybridization (FISH) analysis or copy number variation (CNV) analysis with digital droplet PCR (ddPCR). To determine whether MPM tissue and cell lines were comparable in terms of molecular alterations, IHC marker expression was analyzed in both sample types. The percentage of MPM biomarker levels showed variation between original tissue and matched cells established in culture. Genomic deletions of BAP1 and CDKN2A, however, showed consistent levels between the two. The data from this study suggest that genomic deletion analysis may provide more accurate biomarker options for MPM diagnosis.<\/jats:p>","DOI":"10.3390\/ijms19103056","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T10:44:53Z","timestamp":1538995493000},"page":"3056","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures"],"prefix":"10.3390","volume":"19","author":[{"given":"Kadir Harun","family":"Sarun","sequence":"first","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lee","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"},{"name":"Anatomical Pathology Department, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia"},{"name":"School of Medicine, University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-7676","authenticated-orcid":false,"given":"Marissa","family":"Williams","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"},{"name":"School of Medicine, University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey Maree","family":"Wright","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice Julie","family":"Clarke","sequence":"additional","affiliation":[{"name":"Anatomical Pathology Department, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan Ching","family":"Cheng","sequence":"additional","affiliation":[{"name":"Liver Injury and Cancer Program, Centenary Institute, Sydney, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-2257","authenticated-orcid":false,"given":"Ken","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Yee","family":"Cheng","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW 2139, Australia"},{"name":"School of Medicine, University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1289\/ehp.1002285","article-title":"The case for a global ban on asbestos","volume":"118","author":"LaDou","year":"2010","journal-title":"Environ. Health Perspect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1445-5994.2010.02223.x","article-title":"Malignant mesothelioma","volume":"40","author":"Kao","year":"2010","journal-title":"Intern. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2013.53.1228","article-title":"Recent clinical advances in lung cancer management","volume":"32","author":"Johnson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ajco.12043","article-title":"Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review","volume":"9","author":"Linton","year":"2013","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 Update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-10862-4_5","article-title":"Pathohistological diagnosis and differential diagnosis","volume":"189","author":"Tischoff","year":"2011","journal-title":"Recent Results Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Oehl, K., Vrugt, B., Opitz, I., and Meerang, M. (2018). Heterogeneity in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061603"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1440-1843.2005.00694.x","article-title":"Pathogenesis of malignant pleural mesothelioma","volume":"10","author":"Jaurand","year":"2005","journal-title":"Respirology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","volume":"17","author":"Borczuk","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-08-2755","article-title":"Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma","volume":"15","author":"Ivanova","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_18","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-09-1660","article-title":"Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"16","author":"Dahabreh","year":"2010","journal-title":"Clin Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10616-007-9109-9","article-title":"Tissue culture: The unrealized potential","volume":"57","author":"Sato","year":"2008","journal-title":"Cytotechnology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s11626-010-9315-1","article-title":"Tissue culture: The unlimited potential","volume":"46","author":"Sato","year":"2010","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2009.03.042","article-title":"Tumorigenic properties of alternative osteopontin isoforms in mesothelioma","volume":"382","author":"Ivanov","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S2265","DOI":"10.1016\/j.jtho.2017.09.1607","article-title":"Establishing malignant pleural mesothelioma cell lines using the spheroid method produces a model with better 3D architecture","volume":"12","author":"Cheng","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R1173","DOI":"10.1016\/j.cub.2017.07.026","article-title":"Mesothelioma: Identical Routes to Malignancy from Asbestos and Carbon Nanotubes","volume":"27","author":"Port","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: A multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: A looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5858\/2008-132-397-AOITTD","article-title":"Application of immunohistochemistry to the diagnosis of malignant mesothelioma","volume":"132","author":"Marchevsky","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Relan, V., Morrison, L., Parsonson, K., Clarke, B.E., Duhig, E.E., Windsor, M.N., Matar, K.S., Naidoo, R., Passmore, L., and McCaul, E. (2013). Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058132"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/jcb.25800","article-title":"Protein Expression Differences of 2-Dimensional and Progressive 3-Dimensional Cell Cultures of Non-Small-Cell-Lung-Cancer Cell Line H460","volume":"118","author":"Ravi","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/dc.23501","article-title":"Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations","volume":"44","author":"Nabeshima","year":"2016","journal-title":"Diagn. Cytopathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1590\/S1415-47572014000200006","article-title":"Human molecular cytogenetics: From cells to nucleotides","volume":"37","author":"Riegel","year":"2014","journal-title":"Genet. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cheng, Y.Y., Mok, E., Tan, S., Leygo, C., McLaughlin, C., George, A.M., and Reid, G. (2017). SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. Dis. Mark.","DOI":"10.1155\/2017\/2536187"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J. Clin. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:24:17Z","timestamp":1760196257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,7]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["ijms19103056"],"URL":"https:\/\/doi.org\/10.3390\/ijms19103056","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,7]]}}}